Recently, GLP-1 receptor agonists—medications originally designed to treat diabetes—have gained attention for their remarkable weight loss benefits and their role in blood glucose control.
But how do they work? What makes them different from traditional weight loss methods?
Learning about the science behind GLP-1s can help you make smart choices about your health and wellness.
Weight loss medications like Ozempic, Wegovy, and Mounjaro have surged in popularity, thanks to their ability to help people lose significant amounts of weight. These medications influence hormones that control hunger and blood sugar levels, making them a promising solution for women struggling with weight loss.
But it is important to understand the science behind these treatments and how they work with the body to help people lose weight in a healthy way.
What Are GLP-1 Receptor Agonists, and How Do They Work?
GLP-1 receptor agonists are a group of drugs that work like the hormone glucagon-like peptide-1 (GLP-1), which is naturally made in the gut. This hormone plays a crucial role in regulating appetite, slowing gastric emptying, and managing blood sugar levels.
GLP-1 agonist medications bind to GLP receptors to trigger the effects of the GLP-1 hormone, including increased insulin release and slowed digestion.
The medications help manage blood sugar by triggering the pancreas to release more insulin and also reduce food intake, appetite, and hunger, leading to weight loss. The higher the dose of the GLP-1 agonist, the more extreme the effects.
They are injectable medications, typically given as a subcutaneous injection in the fatty tissue just under the skin. Other names for this medication class include GLP-1 receptor agonists (GLP-1RAs).
GLP-1 medications, on the other hand, extend the hormone’s effects, leading to reduced hunger and improved glucose control by controlling blood glucose levels.
GLP-1s also have a body weight-reducing effect without clinically significant differences in body weight reduction between short-acting and long-acting GLP-1RAs.
GLP-1 agonists alone cannot treat type 2 diabetes or obesity and require other treatment strategies like lifestyle and dietary changes.
Benefits of GLP-1s
GLP-1 receptor agonists (GLP-1RAs) offer a multitude of benefits for managing type 2 diabetes and obesity, making them a valuable tool in modern medicine.
One of the most notable advantages is their ability to promote weight loss. In clinical trials, GLP-1RAs consistently reduce body weight more than placebo, helping people reach their weight management goals.
In addition to weight loss, GLP-1RAs are highly effective in improving blood sugar control. These medications lower blood sugar and improve glycemic control, which type 2 diabetics need. GLP-1RAs prevent blood glucose spikes and crashes by stimulating insulin secretion and decreasing glucagon production.
Cardiovascular health is another area where GLP-1RAs shine. These medications have been shown to reduce the risk of heart attacks and strokes in type 2 diabetics. This makes GLP-1RAs a valuable addition to treat heart disease risk.
Renal benefits are also significant. GLP-1RAs have been shown to reduce the risk of kidney disease and slow its progression in patients with type 2 diabetes. This is particularly important for those with existing renal complications, as maintaining kidney function is critical for overall health.
Emerging research suggests that GLP-1RAs may have neuroprotective effects, potentially offering benefits in the treatment of neurodegenerative diseases like Alzheimer’s and Parkinson’s.
While more studies are needed, these findings open up exciting possibilities for the future use of GLP-1RAs beyond diabetes and obesity management.
The Connection Between GLP-1s and Weight Loss
GLP-1 receptor agonists work in several ways to support weight loss:
- Slows Gastric Emptying: These medications delay the rate at which food leaves the stomach, leading to prolonged feelings of fullness and reduced calorie intake.
- Suppresses Hunger: GLP-1s work on the hypothalamus, which is the part of the brain that controls hunger, to lower cravings and overall food intake.
- Regulates Blood Sugar Levels: GLP-1s increase insulin secretion in response to food while also reducing glucagon production, helping stabilize blood sugar and prevent energy crashes that lead to overeating.
- Enhances Fat Utilization: Some research suggests that GLP-1s promote fat oxidation, encouraging the body to burn stored fat as an energy source.
GLP-1s have been shown to promote weight loss and improve blood sugar control in people with Type 2 diabetes. In clinical trials, they have also been demonstrated to improve glycemic control and decrease body weight.
GLP-1s have a low risk of hypoglycemia and can be used in combination with other diabetes medications. They have also been shown to have a positive effect on cardiovascular health and kidney disease.
Scientific Studies Supporting GLP-1s for Weight Loss
Research strongly supports the effectiveness of GLP-1 receptor agonists for weight loss.
- A 2021 study published in the New England Journal of Medicine found that individuals using semaglutide (Wegovy) lost an average of 15% of their body weight over 68 weeks, compared to just 2.4% in the placebo group.
- A different study in The Lancet Diabetes & Endocrinology found that people who took tirzepatide (Mounjaro), which is an agonist for both GLP-1 and GIP receptors, lost even more weight. Some people lost up to 21% of their body weight.
- Clinical trials have consistently shown that GLP-1s help maintain lean muscle mass while reducing fat stores, making them a more effective long-term weight loss solution compared to crash diets.
GLP-1 Medications: The Most Popular Options
Several GLP-1 medications have been approved for weight loss and diabetes management:
- Semaglutide (Ozempic, Wegovy): Initially developed for diabetes, this medication is now widely used for weight loss.
- Liraglutide (Saxenda, Victoza): Another GLP-1 that has been approved for weight management.
- Dulaglutide (Trulicity): Mainly prescribed for diabetes but may also aid in weight loss.
- Tirzepatide (Mounjaro): A newer medication that targets both GLP-1 and GIP receptors, leading to even greater weight loss.
Are GLP-1s Safe for Women Over 50?
While GLP-1s can be highly effective and lead to significantly reduced body weight, it’s important to understand their potential side effects.
Common side effects include:
- Nausea, vomiting, and diarrhea (especially in the first few weeks)
- Fatigue and dizziness
- Reduced appetite, which can sometimes lead to inadequate nutrition
- Rare but serious risks like pancreatitis and gallbladder issues
For women over 50, the safety of long-term use is still being studied. If you have osteoporosis, heart disease, or digestive disorders, talk to your doctor about whether these medications are right for you.
Safety and Side Effects
While GLP-1 receptor agonists (GLP-1RAs) are generally well-tolerated, it’s important to be aware of potential side effects. Common side effects include nausea and vomiting, particularly when starting treatment. These symptoms often subside as the body adjusts to the medication, but they can be uncomfortable initially.
Diarrhea is another common side effect, especially during the early stages of treatment. Staying hydrated and following a balanced diet can help manage this issue. Injection site reactions, such as redness, swelling, and itching, may also occur but are usually mild and temporary.
There are some more serious risks associated with GLP-1RAs, although they are relatively rare. One such risk is pancreatitis, an inflammation of the pancreas that can cause severe abdominal pain and other symptoms. If you experience persistent pain, it’s crucial to seek medical attention promptly.
Another potential risk is an increased likelihood of thyroid cancer. While the evidence is still limited and inconclusive, it’s important to discuss this risk with your healthcare provider, especially if you have a history of thyroid issues.
Overall, while GLP-1RAs offer significant benefits, it’s essential to weigh these against the potential side effects and risks. Regular monitoring and open communication with your healthcare provider can help ensure that these medications are used safely and effectively.
How to Support Weight Loss While Using GLP-1s
Changes in lifestyle are necessary to get the most out of GLP-1s.
Consider these strategies:
- Prioritize Protein Intake: Since these medications reduce appetite, ensuring adequate protein intake helps preserve muscle mass.
- Incorporate Strength Training: Resistance exercises help counteract age-related muscle loss.
- Stay Hydrated: Many users report dehydration due to reduced food intake, so increasing water consumption is essential.
- Focus on Whole Foods: Avoid processed foods and prioritize fiber-rich vegetables, lean proteins, and healthy fats to maintain balanced nutrition.
- Manage Stress: High cortisol levels can counteract weight loss efforts, so practices like meditation, yoga, and deep breathing can be helpful.
GLP-1s in Diabetes Treatment
GLP-1 receptor agonists, like Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide), were first created to help people with type 2 diabetes.
These medications mimic the gut-produced glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar and lowers it.
Research shows that GLP-1s stimulate insulin secretion, reduce glucagon production, and slow gastric emptying, which helps prevent sharp spikes in blood glucose levels after eating.
Clinical studies have demonstrated that GLP-1s can lower HbA1c levels by 1% to 2% on average, significantly improving blood sugar control in people with Type 2 diabetes.
These medications can be used alone (monotherapy) or in combination with other diabetes treatments, such as metformin, SGLT-2 inhibitors, or insulin, depending on an individual’s needs.
Studies also show that GLP-1s support cardiovascular health by reducing the risk of heart attacks and strokes in people with diabetes. They work differently for everyone, so doctors consider body weight, kidney function, and heart conditions before prescribing them.
GLP-1s have many benefits, but real diabetes management requires a healthy diet, regular exercise, and a sustainable lifestyle.
GLP-1s and Cardiovascular Health
GLP-1 receptor agonists regulate blood sugar, lower it, and improve cardiovascular health. Clinical trials, including the LEADER, SUSTAIN-6, and REWIND studies, have demonstrated that GLP-1 medications can lower the risk of major cardiovascular events, such as heart attacks, strokes, and cardiovascular-related deaths.
These medications lower heart disease risk by reducing inflammation, improving endothelial function, and improving blood vessel health.
Additionally, studies show that GLP-1s can reduce systolic blood pressure by an average of 2-5 mmHg, which helps protect against hypertension-related complications.
Beyond blood pressure control, GLP-1s also improve lipid profiles by lowering LDL (bad cholesterol) and increasing HDL (good cholesterol), further reducing cardiovascular risk. GLP-1 medications are now used in type 2 diabetes and cardiovascular disease patients due to their benefits.
In some cases, they are prescribed alongside other heart-protective medications, such as statins or blood pressure medications, to optimize heart health.
While the research is promising, it’s essential to incorporate a heart-healthy diet, regular physical activity, and stress management for long-term cardiovascular wellness.
GLP-1s and Renal Complications
GLP-1 receptor agonists (GLP-1RAs) have shown promising benefits for patients with type 2 diabetes who are at risk of renal complications.
One of the key advantages is their ability to reduce the risk of kidney disease. Clinical studies show that GLP-1RAs improve blood sugar control and reduce inflammation, which protects the kidneys.
For patients who already have kidney disease, GLP-1RAs can slow its progression. These medications preserve kidney function by lowering blood glucose and kidney strain. Type 2 diabetics are more likely to develop renal complications, making this crucial.
In addition to slowing disease progression, GLP-1RAs have been shown to improve overall kidney function. This includes better filtration rates and reduced proteinuria, which are indicators of healthier kidneys. These benefits make GLP-1RAs a valuable option for managing renal health in patients with type 2 diabetes.
Patients can better control their blood sugar and protect their kidneys by adding GLP-1RAs to their treatment plan. This will ultimately improve their quality of life and long-term health outcomes.
GLP-1s and Liver Diseases
GLP-1 receptor agonists (GLP-1RAs) are also showing promise in the management of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). NAFLD, which causes liver fat accumulation and inflammation, is common in type 2 diabetics and obese people.
One of the key benefits of GLP-1RAs in patients with NAFLD is improved liver function. These medications help reduce liver fat content and improve liver enzyme levels, which are indicators of better liver health.
GLP-1RAs help with some of the causes of NAFLD by making it easier to lose weight and making insulin work better.
In addition to improving liver function, GLP-1RAs have been shown to reduce liver inflammation. Chronic inflammation in NAFLD allows it to cause more serious liver diseases like NASH and cirrhosis. GLP-1RAs help protect the liver from more damage by lowering inflammation.
Another important benefit of GLP-1RAs for people with NAFLD is that they make insulin work better. Insulin resistance is common in NAFLD, and improving insulin sensitivity can reduce liver fat and improve metabolic health.
Overall, GLP-1RAs offer a promising approach to managing liver diseases in patients with type 2 diabetes and obesity.
GLP-1s and Bariatric Surgery
Pre- and post-bariatric surgery GLP-1 receptor agonists are improving weight loss, appetite control, and blood sugar regulation. These medications reduce hunger hormones and increase satiety, making a nutrient-dense, portion-controlled diet easier after surgery.
Studies show that GLP-1s improve insulin sensitivity and glucose metabolism after gastric bypass and sleeve gastrectomy, improving long-term weight management.
GLP-1s stabilize blood sugar, reducing the risk of hypoglycemia and other complications after bariatric surgery, especially in Type 2 diabetics.
Research suggests that post-surgery GLP-1 users have better glycemic control and less weight gain. GLP-1 medications can help post-surgery patients with hunger or metabolic adaptation.
These treatments should be part of a holistic lifestyle plan that includes balanced nutrition, regular exercise, and medical supervision for long-term success.
The Future of GLP-1s in Weight Management
With ongoing research, GLP-1 receptor agonists may become even more refined, offering enhanced weight loss benefits with fewer side effects.
Scientists are developing next-generation medications that provide longer-lasting effects, increased fat burning, and better tolerability.
GLP-1s are revolutionizing the weight loss industry, but they are not a magic solution. Combining these medications with a healthy lifestyle, proper nutrition, and exercise is key to long-term success.
GLP-1s may also have potential as a treatment for other diseases, such as obesity and neurodegenerative diseases.
If you’re considering GLP-1s, consult a healthcare professional to determine the best approach for your body and health goals.
Looking for a Natural Way to Lose Weight Without GLP-1s?
You can achieve real, lasting results naturally, without relying on prescriptions. Focusing on healthy eating, exercise, and lifestyle choices can help speed up your metabolism, keep your blood sugar in check, and help you lose weight in a way that lasts.
That’s why we created the New You 14-Day Challenge—a guided fitness and wellness program designed to do more than what GLP-1s can offer.
Our challenge helps you:
- Burn fat naturally with effective workouts
- Boost metabolism with the right nutrition
- Increase energy without medications
- Build long-term habits for lasting success
Medications may help in weight loss, but they don’t teach you how to keep the weight off. Our challenge gives you the tools, guidance, and motivation to make real progress, naturally.
Join the New You 14-Day Weight Loss Challenge today and start your journey to a healthier, stronger you!
References:
Aroda, V. R., Wharton, S., & Wright, E. M. (2024). GLP-1 receptor agonists and cardiometabolic risk reduction: current evidence and future directions. International Journal of Obesity, 48(7), 875–890. https://www.nature.com/articles/s41366-024-01461-2
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. National Institutes of Health (NIH). https://www.ncbi.nlm.nih.gov/books/NBK551568/
Holst, J. J. (2017). The physiology of glucagon-like peptide 1. Physiological Reviews, 97(2), 439–541. https://pmc.ncbi.nlm.nih.gov/articles/PMC5397288/
Williams, D. L., & Grill, H. J. (2013). Gut-brain signaling and the control of food intake. Physiology & Behavior, 121, 11–17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3556522/
Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., … & Tschöp, M. H. (2018). Glucagon-like peptide-1 receptor agonists as therapeutic strategies. Nature Reviews Drug Discovery, 17(8), 561–586. https://pmc.ncbi.nlm.nih.gov/articles/PMC5902002/
Greenough, A., & Drucker, D. J. (2025). Glucagon-like peptide-1 receptor agonists: A new era in the treatment of obesity. Pharmacology & Therapeutics. https://www.sciencedirect.com/science/article/pii/S0272638625000423
Todd, A. J., & Keating, G. M. (2003). Exenatide: a review of its use in patients with type 2 diabetes mellitus. Drugs, 63(12), 1255–1270. https://pubmed.ncbi.nlm.nih.gov/12540611/
Knop, F. K., & Aroda, V. R. (2023). GLP-1 receptor agonists and cardiovascular outcomes: a review of recent trials. Cardiovascular Diabetology, 22(1), 38. https://pmc.ncbi.nlm.nih.gov/articles/PMC9945324/
Meier, J. J. (2006). Glucagon-like peptide-1 receptor agonists for type 2 diabetes: current concepts and future perspectives. Expert Opinion on Pharmacotherapy, 7(11), 1399–1412. https://pmc.ncbi.nlm.nih.gov/articles/PMC11579408/
Lean, M. E. J., & Astrup, A. (2021). Gut-brain signalling and GLP-1 receptor agonists for obesity. Proceedings of the Nutrition Society, 80(4), 485–493. https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616
Medical News Today. (n.d.). Ozempic and diarrhea: What you need to know. Medical News Today. https://www.medicalnewstoday.com/articles/drugs-ozempic-diarrhea
Drucker, D. J. (2018). Mechanisms of action and therapeutic potential of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://pmc.ncbi.nlm.nih.gov/articles/PMC5808258/
Aroda, V. R., & Davies, M. J. (2022). GLP-1 receptor agonists in type 2 diabetes: a review of recent clinical trials. Expert Review of Endocrinology & Metabolism, 17(6), 661–678. https://pmc.ncbi.nlm.nih.gov/
